Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Issues Earnings Results

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) posted its quarterly earnings results on Thursday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08), FiscalAI reports. The business had revenue of $14.48 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%.

Here are the key takeaways from Senseonics Holdings, Inc. Common Stock’s conference call:

• Q2 revenue rose approximately 120% year over year to $14.5 million, led by U.S. revenue growth of more than 150% and continued adoption of Eversense 365. Management raised full-year 2026 revenue guidance to $62 million-$66 million, implying roughly 80% annual growth.
• Gross margin increased to 59%, the company’s strongest organic performance, supported by manufacturing improvements and a favorable reimbursement mix. Full-year gross margin guidance was raised to 58%-61% from 55%-58%.
• The Eon Care network expanded to more than 90 providers and performed a record number of insertions, accounting for approximately 40% of U.S. insertions in Q2. Management expects Eon to exceed 100 providers and represent more than half of U.S. insertions by year-end.
• The European commercial transition from Ascensia was completed, but delayed tender updates and inventory adjustments pushed some revenue into the third and fourth quarters. Management expects no full-year impact and continues to forecast Europe at approximately 20% of total 2026 revenue.
• Despite stronger revenue and margins, the net loss widened to $36.7 million from $14.5 million a year earlier as selling, general and administrative expenses rose sharply following the commercial transition and investments in Gemini and Freedom. The company expects 2026 operating expenses of $150 million-$160 million and cash utilization of $110 million-$120 million.

Senseonics Holdings, Inc. Common Stock Trading Up 26.2%

NASDAQ:SENS traded up $1.35 during trading hours on Friday, hitting $6.50. 284,748 shares of the stock traded hands, compared to its average volume of 638,101. The business’s 50 day simple moving average is $5.85. The firm has a market capitalization of $271.57 million, a price-to-earnings ratio of -3.25 and a beta of 1.01. Senseonics Holdings, Inc. Common Stock has a fifty-two week low of $4.79 and a fifty-two week high of $11.58. The company has a current ratio of 3.51, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Wall Street Analyst Weigh In

SENS has been the topic of several analyst reports. Mizuho dropped their target price on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Stifel Nicolaus decreased their price target on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Monday, May 11th. HC Wainwright reduced their price objective on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings upgraded Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Senseonics Holdings, Inc. Common Stock has an average rating of “Moderate Buy” and a consensus target price of $17.20.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder purchased 22,686 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were purchased at an average cost of $5.56 per share, with a total value of $126,134.16. Following the completion of the transaction, the director owned 144,635 shares of the company’s stock, valued at approximately $804,170.60. This represents a 18.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Trading of Senseonics Holdings, Inc. Common Stock

Several institutional investors have recently made changes to their positions in SENS. Goldman Sachs Group Inc. increased its stake in Senseonics Holdings, Inc. Common Stock by 26.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 612,534 shares of the company’s stock valued at $402,000 after buying an additional 127,086 shares during the period. Geode Capital Management LLC increased its stake in shares of Senseonics Holdings, Inc. Common Stock by 26.6% in the second quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock worth $4,147,000 after acquiring an additional 1,828,302 shares during the last quarter. Walleye Capital LLC acquired a new position in Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth about $539,000. Sei Investments Co. acquired a new position in Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth about $761,000. Finally, First Light Asset Management LLC raised its stake in shares of Senseonics Holdings, Inc. Common Stock by 666.7% during the 2nd quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company’s stock worth $17,011,000 after purchasing an additional 31,050,619 shares in the last quarter. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.